Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold

Maximilian Koch; Johannes S de Jong; Jürgen Glatz; Panagiotis Symvoulidis; Laetitia E Lamberts; Arthur L.L. Adams; Mariëtte E G Kranendonk; Anton G T Terwisscha van Scheltinga; Michaela Aichler; Liesbeth Jansen; Jakob de Vries; Marjolijn N Lub-de Hooge; Carolien P. Schröder; Annelies Jorritsma-Smit; Matthijs D Linssen; Esther de Boer; Bert van der Vegt; Wouter B Nagengast; Sjoerd G. Elias; Sabrina Oliveira; Arjen J. Witkamp; Willem P.Th M. Mali; Elsken Van der Wall; Beatriz P Garcia-Allende; Paul J. van Diest; Elisabeth G E de Vries; Axel Walch; Gooitzen M van Dam; Vasilis Ntziachristos

doi:10.1117/12.2286062

Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold

Maximilian Koch
, Johannes S de Jong
, Jürgen Glatz
, Panagiotis Symvoulidis
, Laetitia E Lamberts
, Arthur L.L. Adams
, Mariëtte E G Kranendonk
, Anton G T Terwisscha van Scheltinga
, Michaela Aichler
, Liesbeth Jansen
, Jakob de Vries
, Marjolijn N Lub-de Hooge
, Carolien P. Schröder
, Annelies Jorritsma-Smit
, Matthijs D Linssen
, Esther de Boer
, Bert van der Vegt
, Wouter B Nagengast
, Sjoerd G. Elias
, Sabrina Oliveira

Arjen J. Witkamp, Willem P.Th M. Mali, Elsken Van der Wall, Beatriz P Garcia-Allende, Paul J. van Diest, Elisabeth G E de Vries, Axel Walch, Gooitzen M van Dam, Vasilis Ntziachristos

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › Academic › peer-review

Abstract

In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.

Original language	English
Title of host publication	European Conference on Biomedical Optics, ECBO 2017
Publisher	OSA - The Optical Society
Volume	Part F61-ECBO 2017
ISBN (Electronic)	9781557528209
ISBN (Print)	9781510612808
DOIs	https://doi.org/10.1117/12.2286062
Publication status	Published - 2017
Event	European Conference on Biomedical Optics, ECBO 2017 - Munich, Germany Duration: 25 Jun 2017 → 29 Jun 2017

Conference

Conference	European Conference on Biomedical Optics, ECBO 2017
Country/Territory	Germany
City	Munich
Period	25/06/17 → 29/06/17

Keywords

Clinical applications
Imaging systems
Medical and biological imaging

Access to Document

10.1117/12.2286062

Cite this

Koch, M., de Jong, J. S., Glatz, J., Symvoulidis, P., Lamberts, L. E., Adams, A. L. L., Kranendonk, M. E. G., Terwisscha van Scheltinga, A. G. T., Aichler, M., Jansen, L., de Vries, J., Lub-de Hooge, M. N., Schröder, C. P., Jorritsma-Smit, A., Linssen, M. D., de Boer, E., van der Vegt, B., Nagengast, W. B., Elias, S. G., ... Ntziachristos, V. (2017). Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold. In European Conference on Biomedical Optics, ECBO 2017 (Vol. Part F61-ECBO 2017). Article 104110F OSA - The Optical Society. https://doi.org/10.1117/12.2286062

@inproceedings{d2a73a7f8e7d4c269382f83c22c49d09,

title = "Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold",

abstract = "In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.",

keywords = "Clinical applications, Imaging systems, Medical and biological imaging",

author = "Maximilian Koch and \{de Jong\}, \{Johannes S\} and J{\"u}rgen Glatz and Panagiotis Symvoulidis and Lamberts, \{Laetitia E\} and Adams, \{Arthur L.L.\} and Kranendonk, \{Mari{\"e}tte E G\} and \{Terwisscha van Scheltinga\}, \{Anton G T\} and Michaela Aichler and Liesbeth Jansen and \{de Vries\}, Jakob and \{Lub-de Hooge\}, \{Marjolijn N\} and Schr{\"o}der, \{Carolien P.\} and Annelies Jorritsma-Smit and Linssen, \{Matthijs D\} and \{de Boer\}, Esther and \{van der Vegt\}, Bert and Nagengast, \{Wouter B\} and Elias, \{Sjoerd G.\} and Sabrina Oliveira and Witkamp, \{Arjen J.\} and Mali, \{Willem P.Th M.\} and \{Van der Wall\}, Elsken and Garcia-Allende, \{Beatriz P\} and \{van Diest\}, \{Paul J.\} and \{de Vries\}, \{Elisabeth G E\} and Axel Walch and \{van Dam\}, \{Gooitzen M\} and Vasilis Ntziachristos",

note = "Publisher Copyright: {\textcopyright} 2017 SPIE-OSA.; European Conference on Biomedical Optics, ECBO 2017 ; Conference date: 25-06-2017 Through 29-06-2017",

year = "2017",

doi = "10.1117/12.2286062",

language = "English",

isbn = "9781510612808",

volume = "Part F61-ECBO 2017",

booktitle = "European Conference on Biomedical Optics, ECBO 2017",

publisher = "OSA - The Optical Society",

}

Koch, M, de Jong, JS, Glatz, J, Symvoulidis, P, Lamberts, LE, Adams, ALL, Kranendonk, MEG, Terwisscha van Scheltinga, AGT, Aichler, M, Jansen, L, de Vries, J, Lub-de Hooge, MN, Schröder, CP, Jorritsma-Smit, A, Linssen, MD, de Boer, E, van der Vegt, B, Nagengast, WB, Elias, SG, Oliveira, S, Witkamp, AJ, Mali, WPTM, Van der Wall, E, Garcia-Allende, BP, van Diest, PJ, de Vries, EGE, Walch, A, van Dam, GM & Ntziachristos, V 2017, Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold. in European Conference on Biomedical Optics, ECBO 2017. vol. Part F61-ECBO 2017, 104110F, OSA - The Optical Society, European Conference on Biomedical Optics, ECBO 2017, Munich, Germany, 25/06/17. https://doi.org/10.1117/12.2286062

Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold. / Koch, Maximilian; de Jong, Johannes S; Glatz, Jürgen et al.
European Conference on Biomedical Optics, ECBO 2017. Vol. Part F61-ECBO 2017 OSA - The Optical Society, 2017. 104110F.

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › Academic › peer-review

TY - GEN

T1 - Fluorescently labeled bevacizumab in human breast cancer

T2 - European Conference on Biomedical Optics, ECBO 2017

AU - Koch, Maximilian

AU - de Jong, Johannes S

AU - Glatz, Jürgen

AU - Symvoulidis, Panagiotis

AU - Lamberts, Laetitia E

AU - Adams, Arthur L.L.

AU - Kranendonk, Mariëtte E G

AU - Terwisscha van Scheltinga, Anton G T

AU - Aichler, Michaela

AU - Jansen, Liesbeth

AU - de Vries, Jakob

AU - Lub-de Hooge, Marjolijn N

AU - Schröder, Carolien P.

AU - Jorritsma-Smit, Annelies

AU - Linssen, Matthijs D

AU - de Boer, Esther

AU - van der Vegt, Bert

AU - Nagengast, Wouter B

AU - Elias, Sjoerd G.

AU - Oliveira, Sabrina

AU - Witkamp, Arjen J.

AU - Mali, Willem P.Th M.

AU - Van der Wall, Elsken

AU - Garcia-Allende, Beatriz P

AU - van Diest, Paul J.

AU - de Vries, Elisabeth G E

AU - Walch, Axel

AU - van Dam, Gooitzen M

AU - Ntziachristos, Vasilis

PY - 2017

Y1 - 2017

N2 - In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.

AB - In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.

KW - Clinical applications

KW - Imaging systems

KW - Medical and biological imaging

UR - https://www.scopus.com/pages/publications/85032258866

U2 - 10.1117/12.2286062

DO - 10.1117/12.2286062

M3 - Conference contribution

AN - SCOPUS:85032258866

SN - 9781510612808

VL - Part F61-ECBO 2017

BT - European Conference on Biomedical Optics, ECBO 2017

PB - OSA - The Optical Society

Y2 - 25 June 2017 through 29 June 2017

ER -

Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold

Abstract

Conference

Keywords

Access to Document

Other files and links

Fingerprint

Cite this